NASDAQ · HLVX
Healthcare · Biotechnology
$2.09
Down-$0.01 (-0.48%)
Updated Oct 14, 2026, 2:22 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HLVX
1M range · 0 trading sessions · Daily adjusted prices
HLVX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning HLVX.
Company
Market Activity
Research & News
HLVX research
Company profile and research snapshot.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 31, 2025 | HC Wainwright & Co. | Neutral | — |
| Aug 12, 2024 | HC Wainwright & Co. | Neutral | — |
| Jul 9, 2024 | Stifel | Hold | — |
| Jul 9, 2024 | Leerink Partners | Market Perform | — |
| Jul 9, 2024 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jul 19, 2024
HilleVax's stock plummeted after its sole clinical-stage vaccine candidate failed a phase 2b trial for norovirus-related acute gastroenteritis, leading to investor losses.
Benzinga · Jul 9, 2024
HilleVax's (HLVX) short interest has risen 14.66% since its last report, with 20.02% of its shares sold short. This indicates increased bearish sentiment, as short selling is a strategy used to profit from a stock's decline.
Benzinga · Jul 8, 2024
HilleVax's investigational norovirus vaccine HIL-214 failed to meet its primary endpoint in a Phase 2b trial, leading the company to discontinue further development in infants and explore potential adult use.
GlobeNewswire Inc. · Mar 20, 2024
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HLVX.
No results
No recent SID articles mention HLVX.
